Syndax Pharmaceuticals Inc Revenue Growth Rates (SNDX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Syndax Pharmaceuticals Inc   (NASDAQ: SNDX)
 

SNDX's Revenue Growth by Quarter and Year

Syndax Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SNDX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 72.79
1st Quarter March 64.86
FY 137.65

SNDXs Annual Revenue
Syndax Pharmaceuticals Inc 's Revenue in the fiscal year 2025 $ 172.35 millions
Syndax Pharmaceuticals Inc 's Revenue in the fiscal year 2024 $ 23.68 millions
Syndax Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 0.00 millions
Syndax Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 0.00 millions
Syndax Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 139.71 millions




SNDX Revenue second quarter 2026 Y/Y Growth Comment
Syndax Pharmaceuticals Inc reported Revenue surge of 91.75% year on year in the second quarter 2026, to $ 72.79 millions, this is lower than Syndax Pharmaceuticals Inc 's recent average Revenue surge of 612.67%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 33 other companies have achieved higher Revenue growth. While Syndax Pharmaceuticals Inc ' s Revenue jump of 91.75% ranks overall at the positon no. 183 in the second quarter 2026.


SNDX Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 791.67 % - -
3rd Quarter September - 266.96 % - -
2nd Quarter June 91.75 % 984.57 % - -
1st Quarter March 223.65 % - - -
FY   - 627.83 % - -

Financial Statements
Syndax Pharmaceuticals Inc 's second quarter 2026 Revenue $ 72.79 millions SNDX's Income Statement
Syndax Pharmaceuticals Inc 's second quarter 2025 Revenue $ 37.96 millions Quarterly SNDX's Income Statement


SNDX Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 49.29 % -38.56 % -
3rd Quarter September - 20.84 % 257.14 % -
2nd Quarter June 12.22 % 89.42 % - -
1st Quarter March -5.29 % 160.94 % - -
FY (Year on Year)   - 627.83 % - -


Back to SNDX Growth rate Comparisons >> Back to SNDX Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #34
Healthcare Sector #58
Overall #183

Revenue Y/Y Growth Statistics
High Average Low
9109.56 % 612.67 % -22.99 %
(Dec 31 2021)   (Sep 30 2020)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #34
Healthcare Sector #58
Overall #183
Revenue Y/Y Growth Statistics
High Average Low
9109.56 % 612.67 % -22.99 %
(Dec 31 2021)   (Sep 30 2020)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Syndax Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
3165.17 % 188.72 % -100 %
(Sep 30 2021)  


SNDX's II. Quarter Q/Q Revenue Comment
Syndax Pharmaceuticals Inc achieved in the II. Quarter 2026 below company average Revenue rise of 12.22% quarter on quarter, to $ 72.79 millions.

Within Major Pharmaceutical Preparations industry 49 other companies have achieved higher Revenue quarter on quarter growth. While Syndax Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 727.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #50
Healthcare Sector #120
Overall #727
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #50
Healthcare Sector #120
Overall #727
Revenue Q/Q Growth Statistics
High Average Low
3165.17 % 188.72 % -100 %
(Sep 30 2021)  


SNDX's II. Quarter Q/Q Revenue Comment
Syndax Pharmaceuticals Inc achieved in the II. Quarter 2026 below company average Revenue rise of 12.22% quarter on quarter, to $ 72.79 millions.

Within Major Pharmaceutical Preparations industry 49 other companies have achieved higher Revenue quarter on quarter growth. While Syndax Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 727.


Syndax Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 252.00 $ 217.17 $ 172.35 $ 111.55 $ 78.18
Y / Y Revenue Growth (TTM) 222.34 % 396.72 % - - -
Year on Year Revenue Growth Overall Ranking # 46 # 3 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 16.04 % 26.01 % 54.51 % 42.68 % 78.81 %
Seq. Revenue Growth (TTM) Overall Ranking # 183 # 17 # 74 # 126 # 0


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Syndax Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 252 millions, company would post below average annual Revenue growth of 78.81% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Syndax Pharmaceuticals Inc 's Revenue growth from the 64.86% growth in Mar 31 2026.

Among companies within the Healthcare sector 15 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3 to 46.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 34
Healthcare Sector # 16
Overall # 46

Revenue TTM Y/Y Growth Statistics
High Average Low
9109.56 %
 612.67 %
-22.99 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 34
Sector # 58
S&P 500 # 183
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Syndax Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 252 millions, company would post below average annual Revenue growth of -22.99% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Syndax Pharmaceuticals Inc 's Revenue growth from the 64.86% growth in Mar 31 2026.

Among companies within the Healthcare sector 15 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3 to 46.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 34
Healthcare Sector # 16
Overall # 46

Revenue TTM Y/Y Growth Statistics
High Average Low
9109.56 %
612.67 %
-22.99 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 34
Sector # 58
S&P 500 # 183




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
SNDX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Cormedix Inc 156.52%$ 156.515 millions
Ataibeckley Inc 137.00%$ 136.996 millions
Pavmed Inc 135.71%$ 135.714 millions
Xilio Therapeutics Inc 131.22%$ 131.222 millions
Tenon Medical Inc 126.77%$ 126.773 millions
Sonida Senior Living Inc 122.02%$ 122.024 millions
Bridgebio Pharma Inc 120.39%$ 120.392 millions
Autolus Therapeutics Plc118.37%$ 118.367 millions
Neuraxis Inc 115.72%$ 115.717 millions
Renovorx Inc 115.40%$ 115.403 millions
Ars Pharmaceuticals Inc 114.15%$ 114.150 millions
Foghorn Therapeutics Inc 112.68%$ 112.677 millions
60 Degrees Pharmaceuticals Inc 106.04%$ 106.044 millions
Mobia Medical Inc 102.35%$ 102.352 millions
Ptc Therapeutics inc 101.55%$ 101.548 millions
Eton Pharmaceuticals Inc 98.63%$ 98.631 millions
Immunitybio inc 93.91%$ 93.907 millions
Syndax Pharmaceuticals Inc 91.76%$ 91.759 millions
Phathom Pharmaceuticals Inc 88.02%$ 88.021 millions
Fennec Pharmaceuticals Inc 85.18%$ 85.184 millions
Alamar Biosciences Inc 82.08%$ 82.075 millions
Seastar Medical Holding Corp81.95%$ 81.953 millions
Sera Prognostics Inc 76.47%$ 76.471 millions
Innovative Eyewear Inc 74.46%$ 74.459 millions
Madrigal Pharmaceuticals Inc 71.17%$ 71.169 millions
Tg Therapeutics Inc 70.27%$ 70.272 millions
Tarsus Pharmaceuticals Inc 69.41%$ 69.406 millions
Hyperfine Inc 67.70%$ 67.698 millions
Alnylam Pharmaceuticals Inc 66.86%$ 66.856 millions
Emergent Biosolutions Inc 66.29%$ 66.288 millions


About Syndax Pharmaceuticals Inc Revenue Growth Rates (SNDX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Syndax Pharmaceuticals Inc (CIK 1395937).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-332750
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Syndax Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.